Drug:  | 
      ||||
|---|---|---|---|---|
Trial Name:  | 
      SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas  | 
    |||
NCT#:  | 
      ||||
Conditions:  | 
      Gastrointestinal Stromal Tumor; Sarcoma  | 
    |||
Status:  | 
      Completed  | 
    |||
Phase:  | 
      2  | 
      Start Date 10/01/2000  | 
      Age of Trial (yrs) 25.1  | 
    |
Treatment Phase:  | 
      All  | 
    |||
Drug Category:  | 
      VEGFR inhibitor (TKI)  | 
    |||
Strategy:  | 
      Block tumor blood vessel growth  | 
    |||
Trial Type:  | 
      GIST not specified. GIST patients known to be enrolled.  | 
    |||
Other Protocol IDs:  | 
      CDR000006789, DFCI-00002, NCI-330  | 
    |||
Sponsor:  | 
      Dana-Farber,
NCI  | 
    |||
Patient Contact:  | 
      ||||
Contact email:  | 
      ||||
Contact Phone:  | 
      ||||
Randomized:  | 
      ||||
IV or Oral:  | 
      Intravenous  | 
    |||
Trial Notes:  | 
      ||||
Trial Links | 
    
Trial Results | 
    
Drug Information | 
    
| Semaxanib in Wikipedia | 
Name  | 
      Address  | 
      City  | 
      State  | 
      Zip  | 
      Country  | 
    
450 Brookline Ave  | 
        Boston  | 
        MA  | 
        02215-5450  | 
        USA  |